Anemia, Refractory, with Excess of Blasts
"Anemia, Refractory, with Excess of Blasts" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
| Descriptor ID |
D000754
|
| MeSH Number(s) |
C15.378.071.400.080 C15.378.190.625.062.080
|
| Concept/Terms |
Anemia, Refractory, with Excess of Blasts- Anemia, Refractory, with Excess of Blasts
- Leukemia, Smouldering
- Smouldering Leukemia
- RAEM
- Refractory Anemia with Excess of Blasts
- Leukemia, Smoldering
- Leukemias, Smoldering
- Smoldering Leukemia
- Smoldering Leukemias
- RAEB
|
Below are MeSH descriptors whose meaning is more general than "Anemia, Refractory, with Excess of Blasts".
Below are MeSH descriptors whose meaning is more specific than "Anemia, Refractory, with Excess of Blasts".
This graph shows the total number of publications written about "Anemia, Refractory, with Excess of Blasts" by people in this website by year, and whether "Anemia, Refractory, with Excess of Blasts" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anemia, Refractory, with Excess of Blasts" by people in Profiles.
-
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
-
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.
-
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996 May 15; 87(10):4076-81.
-
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996 May; 52(1):42-6.
-
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia. 1996 Jan; 10(1):20-6.
-
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases. Blood. 1995 Nov 01; 86(9):3613-4.
-
TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood. 1995 Aug 15; 86(4):1525-33.
-
Identification of cytogenetically undetected 12p13 translocations and associated deletions with fluorescence in situ hybridization. Genes Chromosomes Cancer. 1995 Jan; 12(1):66-9.
-
Absence of the XIST gene from late-replicating isodicentric X chromosomes in leukaemia. Hum Mol Genet. 1994 Jul; 3(7):1053-9.
-
Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified with fluorescence in situ hybridization. Blood. 1993 Jul 15; 82(2):547-51.